What anesthesia considerations are recommended for a patient undergoing general anesthesia who has a very high bilirubin level?

Anesthesia Considerations for Patients with Very High Bilirubin Under General Anesthesia

Adjust all anesthetic drug doses downward and increase dosing intervals due to impaired hepatic metabolism, maintain mean arterial pressure ≥65 mmHg to preserve hepatic perfusion, and avoid benzodiazepines if any encephalopathy is present. 1

Critical Preoperative Assessment

High bilirubin indicates hepatic dysfunction requiring systematic evaluation before proceeding:

• Determine the cause: Obstructive jaundice versus hepatocellular disease versus hemolysis—each has different implications
• Assess coagulation status: Standard PT/INR inadequately reflects bleeding risk; obtain viscoelastic testing (TEG/ROTEM) if available 2
• Evaluate renal function: High bilirubin can interfere with creatinine measurement techniques, potentially masking acute kidney injury 3
• Check for encephalopathy: Even subclinical encephalopathy dramatically alters anesthetic requirements
• Quantify severity: Use Child-Turcotte-Pugh (CTP) score if cirrhosis is present to guide risk stratification

Hemodynamic Management

Preserve hepatic blood flow as the primary goal:

• Hepatic blood flow drops 35-42% within the first 30 minutes of anesthesia induction 1
• Maintain MAP ≥65 mmHg throughout the case—patients with liver disease have impaired compensatory hepatic artery vasodilation 1
• Use vasoconstrictors (phenylephrine, norepinephrine) to maintain pressure rather than excessive fluid administration
• Consider arterial line placement as peripheral and central arterial pressures may diverge significantly 1
• Trans-esophageal echocardiography is safe even with esophageal varices and superior for volume assessment 1

Anesthetic Drug Selection

The 2025 EASL guidelines provide the most current evidence-based recommendations:

Induction Agents

• Propofol: Safe choice with minimal pharmacokinetic changes in liver disease, normal recovery time 1
• Ketamine: Acceptable for induction only (not maintenance) due to systemic vasoconstriction with minimal splanchnic effects 1
• Avoid benzodiazepines completely if any encephalopathy exists 1

Maintenance

• Volatile anesthetics (isoflurane, sevoflurane, desflurane) are weakly preferred over propofol due to minimal hepatic metabolism 1
• Exception: Use propofol if increased intracranial pressure is a concern 1
• Consider bispectral index monitoring—anesthetic doses are typically overestimated in patients with pre-existing encephalopathy 1

Opioids

• Fentanyl is the safest opioid—no toxic metabolites, usually no dose adjustment needed 1
• Avoid morphine and other long-acting opioids—elimination is significantly delayed 1
• Tramadol can be used cautiously at reduced doses with longer intervals 1

Neuromuscular Blockers

• Use atracurium or cisatracurium—they don't rely on hepatic excretion 1
• Monitor neuromuscular blockade throughout the case 1
• Sugammadex is effective for rocuronium reversal in CTP A patients 1

Regional Anesthesia Considerations

Avoid neuraxial blocks in advanced liver disease:

• Epidural/spinal placement is contraindicated in CTP B and C cirrhosis due to high risk of epidural hematoma from coagulopathy 1
• Peripheral nerve blocks also carry hematoma risk in CTP B/C patients 1
• Regional techniques may be considered in mild liver disease (CTP A) to reduce systemic drug exposure

Fluid Management

• Use balanced crystalloid solutions over 0.9% saline to prevent hyperchloremic acidosis 1
• Avoid hydroxyethyl starch (HES)—associated with acute kidney injury in this population 1
• Albumin may offer advantages over crystalloids for volume replacement based on trauma/sepsis data 1
• Avoid rapid sodium correction—risk of neurological complications 1
• Maintain low circulating volume to reduce portal pressure while ensuring adequate tissue perfusion 1

Monitoring Considerations

• Bispectral index: Helps guide depth of anesthesia since doses are often overestimated 1
• Arterial line: Peripheral-central BP discrepancy is common 1
• TEE: Superior to CVP for volume assessment and safe with varices 1
• Neuromuscular monitoring: Mandatory given altered drug metabolism 1
• Pulse contour cardiac output monitoring becomes unreliable as disease progresses from CTP A to C 1

Critical Pitfalls to Avoid

1. Don't assume normal drug pharmacokinetics—reduce doses and increase intervals as a default 1
2. Don't rely on standard coagulation tests alone—they don't predict bleeding risk accurately 2
3. Don't allow hypotension—even brief periods compromise already tenuous hepatic perfusion 1
4. Don't place epidurals in CTP B/C patients—the hematoma risk is prohibitive 1
5. Don't rapidly correct hyponatremia—risk of osmotic demyelination 1

Postoperative Management

• Co-prescribe laxatives with any opioid use to prevent constipation-induced encephalopathy 1
• Paracetamol is safe but limit to 2-3 grams daily for prolonged use 1
• Avoid NSAIDs completely—risk of renal impairment, hepatorenal syndrome, and GI bleeding 1
• Use immediate-release rather than controlled-release opioid formulations 1

The 2025 EASL guidelines 1 represent the most comprehensive and current evidence for managing these high-risk patients, with strong consensus recommendations that prioritize hepatic perfusion, careful drug selection, and avoidance of regional techniques in advanced disease.